Emerging research presented at the European Congress on Obesity (ECO) in Istanbul underscores a concerning link between increased pancreatic fat content and heightened cardiometabolic risk factors in children and adolescents grappling with obesity. This pioneering study, undertaken by clinicians and researchers affiliated with The Children’s Obesity Clinic, Centre for Obesity Management at Holbæk University Hospital in Denmark, delves into the intricate relationship between pancreatic adiposity and early markers of cardiovascular and metabolic disturbances in the young population.
Obesity in childhood and adolescence poses a formidable challenge worldwide, with an estimated 25 million children and 35 million adolescents affected by metabolic syndrome—a constellation of risk factors predictive of cardiovascular disease and type 2 diabetes. Characterized by abdominal obesity, dyslipidemia, hypertension, and impaired glucose regulation, metabolic syndrome carries profound implications for long-term health outcomes. While the detrimental effects of obesity-induced fat accumulation in critical organs such as the liver and skeletal muscle have been well-documented in adults, the role of pancreatic fat deposition in young individuals remained largely unexplored until now.
The pancreas plays a pivotal role in maintaining glucose homeostasis through its endocrine function, particularly via insulin secretion. In adults, ectopic fat infiltration within pancreatic tissue is closely associated with insulin resistance, metabolic syndrome, hypertension, and type 2 diabetes. However, the degree to which pancreatic lipid accumulation influences cardiometabolic health in children and adolescents with obesity had not been rigorously quantified or linked to clinical markers of disease before this study.
This research leveraged the non-invasive, highly sensitive tool of magnetic resonance spectroscopy (MRS) to quantify pancreatic, hepatic, and visceral fat content in a cohort of 283 young individuals aged 7 to 19 years, nearly half of whom were female. These participants, referred for obesity treatment at The Children’s Obesity Clinic between February 2020 and September 2025, underwent comprehensive physical and biochemical evaluations alongside imaging, enabling a multifaceted assessment of their cardiometabolic profile.
Crucially, the analysis accounted for confounding variables such as age and sex, ensuring that observed associations accurately reflected the impact of pancreatic fat itself rather than demographic influences. Findings revealed that elevated pancreatic fat levels correlated strongly with markers known to predict poor cardiometabolic outcomes, including increased body mass index (BMI), higher waist-to-height ratio—an anthropometric indicator of central adiposity—elevated diastolic blood pressure, and greater liver and visceral fat accumulation.
Moreover, researchers observed a significant association between pancreatic fat and elevated levels of C-peptide, a biomarker indicative of insulin secretion and resistance. Elevated C-peptide levels signal pancreatic beta-cell stress and insufficient insulin action, highlighting the potential mechanistic link between pancreatic fat infiltration and early disturbances in glucose metabolism. These findings collectively position pancreatic adiposity as a critical, though previously underappreciated, contributor to the development of cardiometabolic risk in the pediatric population with obesity.
Interestingly, the study did not find a significant relationship between pancreatic fat and systolic blood pressure, fasting insulin and HOMA-IR (homeostatic model assessment of insulin resistance), fasting glucose levels, markers of liver function such as alanine aminotransferase (ALT), or lipid profile parameters including LDL, HDL, and total cholesterol. This nuanced result suggests that while pancreatic fat accumulation is connected to certain elements of cardiometabolic dysregulation, it may not uniformly impact all conventional biochemical markers of metabolic syndrome in this age group.
The implications of these discoveries are profound. The early identification of increased pancreatic fat could potentially serve as a biomarker to recognize children and adolescents at heightened risk of progressing toward overt cardiometabolic diseases. This could pave the way for targeted interventions aimed at reducing pancreatic fat content, thereby possibly mitigating downstream metabolic consequences before they fully manifest.
However, the study’s cross-sectional nature precludes definitive causal inference—it cannot conclusively establish whether pancreatic fat causes cardiometabolic abnormalities or vice versa. The potential for confounding factors and reverse causation persists, warranting cautious interpretation of the data. Furthermore, the cohort predominantly comprised European Caucasian children and adolescents, limiting the applicability of findings to more ethnically diverse populations. Larger scale, longitudinal studies across varied demographics are essential to validate these results and expand their generalizability.
Future research directions should focus on elucidating whether therapeutic strategies that reduce pancreatic fat in youth with obesity can directly attenuate associated cardiometabolic risks. Interventions encompassing lifestyle modifications, pharmacotherapy, or novel treatments targeting ectopic fat reduction would need rigorous evaluation in controlled settings. Additionally, the mechanistic underpinnings linking pancreatic stellate cell activation, inflammatory pathways, and insulin secretion amidst pancreatic steatosis merit deeper scientific inquiry.
In summary, this study illuminates an emerging facet of pediatric obesity’s impact—pancreatic fat accumulation—as a significant correlate of several key cardiometabolic risk factors. By integrating advanced imaging technologies with comprehensive clinical assessments, researchers have opened a new frontier for early risk stratification and intervention in young populations vulnerable to obesity-related metabolic dysfunction. As global childhood obesity rates continue to rise, insights such as these will be critical for developing effective preventive and therapeutic strategies aimed at curbing the trajectory toward chronic metabolic diseases.
The research team, led by head consultant Jens-Christian Holm from Copenhagen University Hospital Holbæk, emphasizes the clinical importance of measuring pancreatic fat in obesity management programs. They advocate for heightened vigilance and tailored treatment plans that incorporate pancreatic fat assessment to identify high-risk individuals who may benefit from intensified therapeutic approaches. The prospect that reducing pancreatic fat could lower cardiometabolic risk factors offers an exciting avenue for advancing pediatric obesity care.
Acknowledging study limitations, the authors call for further longitudinal investigations and larger, ethnically diverse cohorts to corroborate their initial findings. They also suggest exploring the biological pathways by which pancreatic fat influences systemic metabolic health to better understand and target this phenomenon. Meanwhile, the current evidence serves as a compelling rationale for including pancreatic fat evaluation within the holistic assessment of young people with severe obesity.
In conclusion, the demonstration that pancreatic fat content associates with detrimental cardiometabolic indicators in children and adolescents highlights an urgent clinical need. Early detection and management of this fatty infiltration could transform approaches to pediatric obesity treatment, ultimately reducing the burden of metabolic syndrome and related diseases in later life. This study marks a significant advance toward unraveling the complex interplay between organ-specific fat deposition and metabolic health in the vulnerable young population.
Subject of Research: Pancreatic fat content and its association with cardiometabolic risk factors in children and adolescents with obesity
Article Title: Not specifically provided in the source content
News Publication Date: 31-Mar-2026
Keywords: Pediatric obesity, pancreatic fat, cardiometabolic risk, magnetic resonance spectroscopy, metabolic syndrome, insulin resistance, childhood metabolic health
Tags: cardiometabolic health risks in childrenchildhood obesity and metabolic syndromechildhood obesity and type 2 diabetes riskearly markers of cardiovascular risk in adolescentsexcess pancreatic fat in obese youthimpact of pancreatic fat on insulin secretionmetabolic disturbances in obese adolescentsobesity-induced pancreatic fat accumulationobesity-related ectopic fat depositionpancreatic adiposity and cardiometabolic riskpancreatic fat and insulin resistancepediatric obesity and glucose homeostasis
